Athersys Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.415
- Today's High:
- $0.456
- Open Price:
- $0.45
- 52W Low:
- $0.5031
- 52W High:
- $10.5
- Prev. Close:
- $0.44
- Volume:
- 108730
Company Statistics
- Market Cap.:
- $21.08 million
- Book Value:
- -1.681
- Revenue TTM:
- $2.41 million
- Operating Margin TTM:
- -2151.26%
- Gross Profit TTM:
- $-65566000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -97.44%
- Return on Equity TTM:
- -1276.02%
Company Profile
Athersys Inc had its IPO on 2007-06-12 under the ticker symbol ATHX.
The company operates in the Healthcare sector and Biotechnology industry. Athersys Inc has a staff strength of 24 employees.
Stock update
Shares of Athersys Inc opened at $0.45 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.42 - $0.46, and closed at $0.46.
This is a +3.64% increase from the previous day's closing price.
A total volume of 108,730 shares were traded at the close of the day’s session.
In the last one week, shares of Athersys Inc have slipped by -2.98%.
Athersys Inc's Key Ratios
Athersys Inc has a market cap of $21.08 million, indicating a price to book ratio of 219.5723 and a price to sales ratio of 2.3399.
In the last 12-months Athersys Inc’s revenue was $2.41 million with a gross profit of $-65566000 and an EBITDA of $-50685000. The EBITDA ratio measures Athersys Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Athersys Inc’s operating margin was -2151.26% while its return on assets stood at -97.44% with a return of equity of -1276.02%.
In Q1, Athersys Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.7%.
Athersys Inc’s PE and PEG Ratio
- Forward PE
- 0.8594
- Trailing PE
- 0
- PEG
- -0.34
Its diluted EPS in the last 12-months stands at $-4.38 per share while it has a forward price to earnings multiple of 0.8594 and a PEG multiple of -0.34. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Athersys Inc’s profitability.
Athersys Inc stock is trading at a EV to sales ratio of 1.0663 and a EV to EBITDA ratio of -0.077. Its price to sales ratio in the trailing 12-months stood at 2.3399.
Athersys Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $27.73 million
- Total Liabilities
- $42.36 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.65 million
- Dividend Payout Ratio
- 0%
Athersys Inc ended 2024 with $27.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $27.73 million while shareholder equity stood at $-23851000.00.
Athersys Inc ended 2024 with $0 in deferred long-term liabilities, $42.36 million in other current liabilities, 18000.00 in common stock, $-655878000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.04 million and cash and short-term investments were $9.04 million. The company’s total short-term debt was $746,000 while long-term debt stood at $0.
Athersys Inc’s total current assets stands at $15.67 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $716000.00 compared to accounts payable of $37.16 million and inventory worth $0.
In 2024, Athersys Inc's operating cash flow was $0 while its capital expenditure stood at $1.65 million.
Comparatively, Athersys Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.46
- 52-Week High
- $10.5
- 52-Week Low
- $0.5031
- Analyst Target Price
- $5.5
Athersys Inc stock is currently trading at $0.46 per share. It touched a 52-week high of $10.5 and a 52-week low of $10.5. Analysts tracking the stock have a 12-month average target price of $5.5.
Its 50-day moving average was $0.6 and 200-day moving average was $0.96 The short ratio stood at 8.51 indicating a short percent outstanding of 0%.
Around 64.6% of the company’s stock are held by insiders while 1049.7% are held by institutions.
Frequently Asked Questions About Athersys Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.